Analyst firms · Raymond James · AVTR
Raymond James AVTR price target and rating history
Avantor Inc. (AVTR) · Health Care
Raymond James rates Avantor Inc. (AVTR) Mkt Perform with a $43 price target, as of its latest action on Nov 4, 2025. It has published 4 rating actions on AVTR since August 2021, including 0 upgrades and 1 downgrade. Across 8 firms with a AVTR price target in the last 12 months, the median target is $11.25.
- Current rating
- Mkt Perform
- Price target
- $43
- Median target, all firms
- $11.25
- Actions on AVTR
- 4
Raymond James price target on AVTR
Every Raymond James rating on AVTR
- Nov 4, 2025
- Feb 7, 2022
- Nov 1, 2021
- Aug 30, 2021
How other firms rate AVTR
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Neutral | $16 | Sep 9, 2026 |
| Jefferies | Hold | $13 | Jul 29, 2026 |
| Bernstein | Mkt Perform | $10.50 | Jun 26, 2026 |
| Wolfe Research | Underperform | $7 | Jun 2, 2026 |
| RBC Capital Markets | Sector Perform | $9 | May 15, 2026 |
| Barclays | Underweight | $8.50 | Mar 6, 2026 |
| Evercore ISI | In-line | $12 | Jan 5, 2026 |
| BofA Securities | Neutral | $13 | Dec 15, 2025 |
Questions about Raymond James and AVTR
- What is Raymond James's price target for AVTR?
- Raymond James's latest stated price target for Avantor Inc. (AVTR) is $43, from its action on Feb 7, 2022.
- What is Raymond James's rating on AVTR?
- Raymond James rates AVTR Mkt Perform, a neutral rating, as of Nov 4, 2025.
- When did Raymond James last change its view on AVTR?
- On Nov 4, 2025, Raymond James downgrades to Mkt Perform from Outperform.
- How does Raymond James's AVTR target compare with other analysts?
- Across 8 firms with a AVTR price target in the last 12 months, the median target is $11.25.
More AVTR rating histories
All Raymond James ratingsAVTR news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.